Vivos Therapeutics, Inc. (VVOS)
NASDAQ: VVOS · Real-Time Price · USD
2.310
-0.230 (-9.06%)
At close: May 19, 2025, 4:00 PM
2.400
+0.090 (3.90%)
After-hours: May 19, 2025, 7:43 PM EDT
Vivos Therapeutics Revenue
Vivos Therapeutics had revenue of $3.02M in the quarter ending March 31, 2025, a decrease of -11.79%. This brings the company's revenue in the last twelve months to $14.63M, up 9.47% year-over-year. In the year 2024, Vivos Therapeutics had annual revenue of $15.03M with 8.91% growth.
Revenue (ttm)
$14.63M
Revenue Growth
+9.47%
P/S Ratio
1.14
Revenue / Employee
$134,202
Employees
109
Market Cap
13.60M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
VVOS News
- 4 days ago - Vivos Therapeutics, Inc. (VVOS) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 5 days ago - Vivos Therapeutics Schedules Release of First Quarter 2025 Financial Results and Conference Call - GlobeNewsWire
- 4 weeks ago - Vivos Therapeutics Signs Definitive Agreement to Acquire Largest Sleep Center Operator in Nevada - GlobeNewsWire
- 6 weeks ago - Vivos Therapeutics, Inc. (VVOS) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 7 weeks ago - Vivos Therapeutics Reports Full Year 2024 Financial Results and Provides Operational Update - GlobeNewsWire
- 7 weeks ago - Vivos Therapeutics Schedules Release of Full Year 2024 Financial Results and Conference Call - GlobeNewsWire
- 5 months ago - Vivos Therapeutics Announces $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - GlobeNewsWire
- 6 months ago - Vivos Therapeutics, Inc. (VVOS) Q3 2024 Earnings Call Transcript - Seeking Alpha